Data may be delayed — last successful sync 2026-09-26 (18 days ago). Figures reflect the most recent completed ingest.
Company profile
MaxCyte, Inc.
NASDAQ: MXCT · Healthcare · Biotechnology
#540 of 1,417 Healthcare companies by revenue35th-percentile growth
EA Score
48DFH 54DQ 40GM 44SS 48
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, Piotroski F
Methodology →Revenue TTM
$32.3M
Rev growth YoY (TTM)
-14.3%
Net income (FY)
-$44.6M
Employees
91
as of 2026-09-15
Market cap
$125.9M
as of 2026-09-15
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$21.0M$21.0M2025
Net income-$44.6M-$44.6M2025
Operating income-$51.9M-$51.9M2025
Total assets$202.5M$202.5M2025
Liabilities$31.0M$31.0M2025
Equity$171.5M$171.5M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product60%
License40%
By geography
UNITED STATES64%
Non-US36%
The read
What is MaxCyte, Inc.’s revenue?
MaxCyte, Inc. booked $21.0M in FY2025 revenue, contracting 5.7% year over year — slower than 65% of Healthcare companies we track, at a -213.0% net margin.
Peers · Healthcare
Item 9 Labs Corp.——SQZ Biotechnologies Company——Alector, Inc.41DSCYNEXIS, Inc.61CEvofem Biosciences, Inc.42DAcutus Medical, Inc.——Neighbors
Montgomery →Key facts
CEOMaher Masoud
SectorHealthcare
IndustryBiotechnology
HeadquartersRockville, MD
ExchangeNASDAQ: MXCT
Employees91
IPO date2021-07-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.